What is peripheral T-cell lymphoma?
Peripheral T-cell lymphoma (PTCL) is the name for a group of uncommon lymphomas that start in mature T cells or, less often, in natural killer (NK) cells. These are white blood cells that normally help the body fight infection. “Peripheral” means that the cells have already matured and left the thymus gland, where T cells develop.
PTCL is not one disease. The World Health Organization (WHO) and the International Consensus Classification (ICC) recognise more than 30 different types. Some mainly affect lymph nodes, while others start in the nose, gut, liver and spleen, skin or blood.
Most types of PTCL are aggressive and need treatment soon after diagnosis. Results with standard chemotherapy are poorer than for most B-cell lymphomas, so care in a specialist lymphoma centre and joining clinical trials are encouraged.
This article covers the systemic (non-skin) forms of PTCL. Lymphomas that start in the skin, such as mycosis fungoides and Sezary syndrome, are usually managed as a separate group.
1. How common is it?
T-cell lymphomas make up less than 15% of all non-Hodgkin lymphomas in Western countries. They are more common in East Asia, partly because of viruses such as Epstein-Barr virus (EBV) and human T-lymphotropic virus type 1 (HTLV-1).
| Feature | Details |
|---|---|
| Typical age | Median about 60-65; ALK-positive anaplastic large cell lymphoma mainly affects children and young adults |
| Sex | Slightly more common in men |
| Most common types | PTCL not otherwise specified (about 1 in 4 cases), angioimmunoblastic type (about 1 in 5) and anaplastic large cell lymphoma |
| Geographic differences | NK/T-cell lymphoma is more common in East Asia and Latin America; adult T-cell leukaemia/lymphoma in south-west Japan, the Caribbean, parts of South America and Africa |
In a large international study of more than 1,100 confirmed cases, the most frequent types were PTCL not otherwise specified (26%), angioimmunoblastic T-cell lymphoma (19%), NK/T-cell lymphoma (10%) and adult T-cell leukaemia/lymphoma (10%). The same study found that about 1 in 10 cases had first been wrongly classified, which shows why expert review of the biopsy matters.
2. Types of PTCL
The two current classifications, the WHO 5th edition and the ICC, both published in 2022, group the main types in a similar way. Some names differ slightly between the two.
| Group | Main types | Key features |
|---|---|---|
| Nodal (lymph node) types | PTCL not otherwise specified (PTCL-NOS) | The most common type; a “diagnosis of exclusion” when no other type fits |
| Nodal | Nodal T follicular helper (TFH) cell lymphoma, angioimmunoblastic type (AITL) | Widespread lymph nodes, rash, fever and immune problems; usually older adults |
| Nodal | Nodal TFH cell lymphoma, follicular type and NOS | Related to AITL and treated in the same way |
| Nodal | EBV-positive nodal T- and NK-cell lymphoma | New in the 2022 classifications; more common in East Asia; poor outlook |
| Anaplastic large cell lymphoma (ALCL) | ALK-positive ALCL | Children and young adults; best outlook of all PTCL types |
| ALCL | ALK-negative ALCL | Older adults; outlook depends on genetic subtype |
| ALCL | Breast implant-associated ALCL | Fluid or a lump around a textured breast implant |
| Extranodal types | Extranodal NK/T-cell lymphoma | Usually starts in the nose; always linked with EBV |
| Extranodal | Enteropathy-associated T-cell lymphoma (EATL) | Small bowel; linked with coeliac disease |
| Extranodal | Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) | Small bowel; not linked with coeliac disease |
| Extranodal | Hepatosplenic T-cell lymphoma | Liver, spleen and bone marrow; often young men |
| Leukaemic types | Adult T-cell leukaemia/lymphoma (ATLL) | Caused by HTLV-1 infection |
| Leukaemic | T-cell prolymphocytic leukaemia and others | Mainly in the blood and bone marrow |
Primary cutaneous ALCL and other skin T-cell lymphomas are classified separately and usually have a much better outlook.
3. Causes and risk factors
For most people with PTCL, no clear cause is found. It is not passed on in families and it is not contagious. Some types have known links.
| Risk factor | Linked type |
|---|---|
| HTLV-1 infection | Adult T-cell leukaemia/lymphoma; only a small minority of carriers develop it, usually decades after infection |
| Epstein-Barr virus (EBV) | Extranodal NK/T-cell lymphoma, EBV-positive nodal lymphoma; EBV-infected B cells are also common in AITL |
| Coeliac disease | Enteropathy-associated T-cell lymphoma, especially if coeliac disease does not respond to a gluten-free diet |
| Textured breast implants | Breast implant-associated ALCL, usually about 8-10 years after the implant |
| Long-term immune suppression | Hepatosplenic T-cell lymphoma, for example after combined thiopurine and anti-TNF treatment for inflammatory bowel disease |
Genetic changes in the lymphoma cells
The lymphoma cells carry acquired genetic changes that are not inherited. In angioimmunoblastic and other TFH lymphomas, changes in TET2, DNMT3A, IDH2 and RHOA are common.
ALK-positive ALCL is defined by a rearrangement of the ALK gene, most often the t(2;5) translocation that joins NPM1 and ALK. In ALK-negative ALCL, a DUSP22 rearrangement is linked with a better outlook, while a TP63 rearrangement is linked with a poorer one.
4. How does it look?
PTCL is usually not visible from the outside, except when it affects the skin, nose or lymph nodes in the neck.
4.1 On the body
- Swollen lymph nodes: firm, usually painless lumps in the neck, armpits or groin. In AITL they are often present in many areas at once.
- Skin rash: an itchy, red, spotty rash is common in AITL. Other types can cause red or purple lumps, plaques or ulcers.
- Nose and face: in NK/T-cell lymphoma there may be swelling of the nose or face, crusting, a sore that does not heal or, in advanced cases, a hole in the palate.
- Swollen abdomen: from an enlarged liver or spleen, or from fluid.
- Breast: in implant-associated ALCL, the breast swells because fluid collects around the implant, sometimes with a lump.
4.2 On scans
On a PET-CT scan, most types of PTCL take up the radioactive sugar tracer strongly and show as bright areas in lymph nodes or organs. CT can show enlarged lymph nodes, an enlarged spleen or liver, thickened bowel or fluid in the chest or abdomen.
4.3 Under the microscope
The pathologist sees that the normal structure of the lymph node or tissue has been replaced by abnormal T cells. These may be small, medium or large and often have irregular nuclei.
| Type | Typical appearance |
|---|---|
| PTCL-NOS | Sheets of medium to large abnormal T cells, often mixed with inflammatory cells |
| AITL | Mixed population of cells, many small branching blood vessels and expanded networks of follicular dendritic cells |
| ALCL | Large “hallmark” cells with horseshoe-shaped nuclei; strong CD30 on all tumour cells |
| NK/T-cell lymphoma | Tumour cells around and inside blood vessel walls, with areas of dead tissue (necrosis) |
Special stains (immunohistochemistry) show the T-cell or NK-cell markers, which markers are lost and whether the cells express CD30, ALK or TFH markers such as PD-1, CXCL13 and ICOS. Tests for EBV (EBER in situ hybridisation) and for clonal T-cell receptor gene rearrangement help to confirm the diagnosis.
5. Symptoms
Symptoms depend on the type of PTCL and where it grows. They often develop over weeks to a few months.
5.1 General symptoms
| Symptom | What it is like |
|---|---|
| Swollen lymph nodes | Painless lumps that do not go away |
| Fever | Unexplained temperature above 38 C, often coming and going |
| Night sweats | Drenching sweats that soak night clothes or bedding |
| Weight loss | Losing more than 10% of body weight within 6 months without trying |
| Tiredness | Persistent exhaustion that does not improve with rest |
| Itching | Widespread itch, sometimes with a rash |
Fever, night sweats and weight loss are called B symptoms. They are common in PTCL and are recorded as part of the stage.
5.2 Symptoms of specific types
| Type | Typical symptoms |
|---|---|
| AITL | Many swollen nodes, rash, fever, fluid around the lungs or in the legs, joint pain; blood tests may show anaemia caused by the immune system and high antibody levels |
| NK/T-cell lymphoma | Blocked nose on one side, nosebleeds, discharge, facial swelling or pain |
| EATL and MEITL | Abdominal pain, diarrhoea, weight loss; sometimes a sudden bowel blockage or perforation |
| Hepatosplenic T-cell lymphoma | Fever, abdominal discomfort from a large spleen, low blood counts |
| ATLL | Swollen nodes, skin lesions, high calcium (thirst, confusion, constipation), frequent infections |
| Implant-associated ALCL | Swelling of one breast, usually years after implant surgery |
When to see a doctor
See a doctor if you have a lump that has lasted more than 2-3 weeks, or recurring fevers, night sweats or weight loss without an obvious cause. A blocked nose with bleeding on one side that does not settle, or new swelling of a breast with an implant, also needs checking. Most of these symptoms have harmless causes, but they should be investigated.
6. Diagnosis
6.1 Biopsy
The diagnosis needs a biopsy. Removing a whole lymph node, or a large piece of tissue, is preferred because PTCL can be hard to recognise in small samples. A core needle biopsy may be used when surgery is not possible.
The sample should be reviewed by a haematopathologist with experience in T-cell lymphoma. In breast implant-associated ALCL, fluid around the implant is drawn off and tested for CD30-positive cells.
6.2 Staging and other tests
| Test | Purpose |
|---|---|
| PET-CT | Shows where the lymphoma is and is used to assess response to treatment |
| Bone marrow biopsy | Checks for spread to the marrow, especially when PET-CT is unclear |
| Blood tests | Blood count, kidney and liver function, LDH, calcium, beta-2 microglobulin |
| Virus tests | HIV, hepatitis B and C; HTLV-1 if ATLL is possible; EBV DNA in the blood for NK/T-cell lymphoma |
| Heart tests | Echocardiogram before doxorubicin |
| MRI of the head and neck | For NK/T-cell lymphoma of the nose |
| Lumbar puncture | In selected high-risk cases, to check the fluid around the brain |
6.3 Stage
PTCL is staged with the Lugano classification, which is based on the older Ann Arbor system.
| Stage | Meaning |
|---|---|
| I | One lymph node group, or one organ outside the lymph nodes |
| II | Two or more lymph node groups on the same side of the diaphragm |
| III | Lymph nodes on both sides of the diaphragm, or nodes above the diaphragm plus the spleen |
| IV | Widespread involvement of one or more organs outside the lymph nodes, such as bone marrow, liver or lung |
Stages I and II are called limited stage, and stages III and IV advanced stage. Most people with nodal PTCL have advanced-stage disease at diagnosis.
6.4 Prognostic scores
Doctors use simple scores to estimate the outlook. The most widely used is the International Prognostic Index (IPI), which gives one point for each of five factors. The Italian Prognostic Index for PTCL (PIT) was designed for PTCL-NOS.
| Score | Factors counted (one point each) |
|---|---|
| IPI | Age over 60; stage III or IV; raised LDH; reduced fitness (ECOG performance status 2 or more); more than one site outside the lymph nodes |
| PIT | Age over 60; raised LDH; ECOG performance status 2 or more; bone marrow involvement |
In the original PIT study, about 62% of patients with no risk factors were alive after 5 years, compared with about 18% of those with 3 or 4 factors. Other scores exist for NK/T-cell lymphoma and ATLL.
7. Treatment
Treatment depends on the type of PTCL, the stage, the person’s age and fitness and whether the lymphoma cells express CD30. It should be planned by a specialist lymphoma team, and a clinical trial should be considered whenever one is available.
7.1 First treatment for nodal PTCL
| Treatment | What it involves | Key points |
|---|---|---|
| CHOP | Cyclophosphamide, doxorubicin, vincristine and prednisone, every 3 weeks for 6 cycles | The long-standing standard; cures only a minority of people with PTCL-NOS or AITL |
| CHOEP | CHOP plus etoposide | Often used in fit people up to about 60; German data showed better event-free survival, mainly in ALK-positive ALCL |
| Brentuximab vedotin + CHP (BV-CHP) | CD30-targeted antibody-drug conjugate replaces vincristine | For CD30-positive PTCL, especially systemic ALCL; improved survival compared with CHOP in the ECHELON-2 trial |
| Autologous stem cell transplant | High-dose chemotherapy followed by return of the patient’s own stem cells | Often offered to fit patients in first remission, except low-risk ALK-positive ALCL |
| Radiotherapy | Involved-site radiotherapy | Mainly for limited-stage disease after shorter chemotherapy |
In the ECHELON-2 trial, 452 people with CD30-positive PTCL received either BV-CHP or CHOP. After 5 years, 51% of those given BV-CHP were alive without progression compared with 43% after CHOP, and overall survival was 70% compared with 61%. About 70% of patients in the trial had systemic ALCL, and the benefit was clearest in this group.
BV-CHP was approved in the United States in 2018 for previously untreated systemic ALCL and other CD30-positive PTCL. In Europe its approval covers systemic ALCL only.
Adding other drugs to CHOP has not been proven to help. In the Ro-CHOP trial, adding romidepsin did not improve survival and caused more side effects.
7.2 Role of stem cell transplant
In the Nordic NLG-T-01 study, people up to 67 years old received six cycles of CHOEP every 2 weeks, followed by an autologous transplant in those who responded. After 5 years, 51% were alive and 44% were alive without progression. This approach is widely used, although it has never been tested against chemotherapy alone in a randomised trial.
An allogeneic transplant, using stem cells from a donor, carries more risk. It is mainly used for relapsed disease and for very aggressive types such as hepatosplenic T-cell lymphoma and ATLL.
7.3 Treatment of other types
| Type | Usual approach |
|---|---|
| ALK-positive ALCL | CHOP, CHOEP or BV-CHP; transplant not usually needed in first remission if low risk |
| Extranodal NK/T-cell lymphoma | Asparaginase-based chemotherapy (for example P-GemOx, DDGP or SMILE) plus radiotherapy of at least 50 Gy for localised disease; CHOP works poorly |
| EATL and MEITL | Intensive chemotherapy, often followed by autologous transplant; nutrition support and sometimes bowel surgery |
| Hepatosplenic T-cell lymphoma | Intensive non-CHOP chemotherapy followed by allogeneic transplant |
| ATLL | Depends on subtype; chemotherapy, antiviral therapy with zidovudine and interferon, mogamulizumab (approved in Japan) and allogeneic transplant |
| Breast implant-associated ALCL | Removal of the implant and the entire surrounding capsule; usually curative if confined to the capsule |
7.4 Relapsed or refractory PTCL
When PTCL comes back or does not respond, a new biopsy is often taken. Fit patients who respond to further treatment may be offered a stem cell transplant.
| Treatment | How it works | Notes |
|---|---|---|
| Brentuximab vedotin | Delivers a toxin to CD30-positive cells | Highly active in ALCL; can be given again if it worked before |
| Crizotinib and other ALK inhibitors | Block the abnormal ALK protein | For ALK-positive ALCL; crizotinib is approved for children and young adults |
| Pralatrexate | Antifolate chemotherapy | US accelerated approval only; responses in about 1 in 4 patients |
| Belinostat | Histone deacetylase (HDAC) inhibitor | US accelerated approval only; responses in about 1 in 4 patients |
| Combination chemotherapy | For example GDP, ICE or DHAP | Used mainly to prepare for transplant |
| Clinical trials | New targeted drugs, antibodies and cell therapies | Strongly encouraged |
The US approval of romidepsin for relapsed PTCL was withdrawn in 2021, because the confirmatory trial did not show a benefit. Pralatrexate, belinostat and romidepsin are not approved for PTCL in Europe.
PD-1 checkpoint inhibitors can work in NK/T-cell lymphoma. However, they are not a standard treatment for other types and can make ATLL worse.
7.5 Supportive care
Chemotherapy for PTCL lowers immunity. Supportive care often includes medicines to prevent infections such as pneumocystis pneumonia and shingles, growth factor injections to boost white cells, and monitoring for hepatitis B reactivation. Fertility preservation should be discussed before treatment in younger people.
8. Prognosis
The outlook varies widely between types. Overall, about 30-40% of people with PTCL are alive five years after diagnosis, according to the US National Cancer Institute.
| Type | Approximate 5-year overall survival |
|---|---|
| ALK-positive ALCL | 70-80% |
| ALK-negative ALCL | About 50% |
| PTCL-NOS | About 30% |
| AITL | About 30% |
| Extranodal NK/T-cell lymphoma | Good for localised nasal disease treated with radiotherapy; poor if widespread |
| EATL, hepatosplenic T-cell lymphoma, ATLL | About 20% or less |
These figures are mostly based on patients treated before newer approaches were widely used. Survival is better for younger people, those with low IPI scores and those who achieve a complete remission.
Results vary a lot from person to person, and figures for a whole group cannot predict what will happen to one individual.
9. Follow-up and living with PTCL
9.1 Follow-up
After treatment ends, people are usually seen every 3 months in the first year and then every 6 months for the next few years. Visits include a check of symptoms, an examination and blood tests.
Routine scans are not recommended if there are no symptoms and the lymphoma is in complete remission. For NK/T-cell lymphoma, EBV DNA in the blood is measured regularly as a marker of the disease.
9.2 Long-term effects
| Possible late effect | What helps |
|---|---|
| Heart problems after doxorubicin | Heart checks if symptoms develop; control of blood pressure and cholesterol |
| Nerve damage (neuropathy) after vincristine or brentuximab vedotin | Usually improves over months; physiotherapy and pain relief |
| Infections | Vaccinations (no live vaccines during and soon after treatment) |
| Second cancers | Usual cancer screening; report new symptoms |
| Fatigue and low mood | Gradual exercise, psychological support and support groups |
9.3 Everyday life
- Report fevers, new lumps, night sweats or weight loss to your team promptly.
- Keep vaccinations up to date, including the yearly flu vaccine, after discussing timing with your team.
- Regular physical activity, a balanced diet and not smoking help recovery.
- Lymphoma charities offer information, helplines and contact with others who have had PTCL.
Resources
- Alaggio, R. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms’, Leukemia, 36(7), pp. 1720-1748.
- Campo, E. et al. (2022) ‘The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee’, Blood, 140(11), pp. 1229-1253.
- Vose, J., Armitage, J. and Weisenburger, D. (2008) ‘International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes’, Journal of Clinical Oncology, 26(25), pp. 4124-4130.
- Gallamini, A. et al. (2004) ‘Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study’, Blood, 103(7), pp. 2474-2479.
- Schmitz, N. et al. (2010) ‘Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group’, Blood, 116(18), pp. 3418-3425.
- d’Amore, F. et al. (2012) ‘Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01’, Journal of Clinical Oncology, 30(25), pp. 3093-3099.
- Horwitz, S. et al. (2019) ‘Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial’, The Lancet, 393(10168), pp. 229-240.
- Horwitz, S. et al. (2022) ‘The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma’, Annals of Oncology, 33(3), pp. 288-298.
- Bachy, E. et al. (2022) ‘Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA)’, Journal of Clinical Oncology, 40(3), pp. 242-251.
- d’Amore, F. et al. (2025) ‘Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment and follow-up’, Annals of Oncology, 36(6), pp. 626-644.
- National Cancer Institute (2025) Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lymphoma/hp/peripheral-t-cell-lymphoma-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.